Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics
GET POWR RATINGS... FREE!
MNMD Stock Price Chart Interactive Chart >
MNMD Price/Volume Stats
| Current price | $2.70 | 52-week high | $32.25 |
| Prev. close | $2.70 | 52-week low | $2.35 |
| Day low | $2.64 | Volume | 227,100 |
| Day high | $2.74 | Avg. volume | 590,216 |
| 50-day MA | $3.31 | Dividend yield | N/A |
| 200-day MA | $10.43 | Market Cap | 101.44M |
Mind Medicine (MindMed) Inc. (MNMD) Company Bio
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
Latest MNMD News From Around the Web
Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.
7 F-Rated Stocks to Sell Before We Reach ChristmasWhile you’re looking for the perfect holiday bargains to put under the tree, this is also an ideal time to clear your portfolio from F-rated stocks to sell. |
Activist Investor Informs MindMed of Financial Misstatements, Questions Internal ControlsSHERIDAN, Wyo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDINGS, LLC (“FCM”) announces that it has sent a letter (the “Letter”) to the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (“MindMed”, the “Company”). On November 10, 2022, MindMed filed with the Securities and Exchange Commission (the “SEC”) form 10-Q for quarter three of 2022 (the “ER”). The Letter focuses on false statements made by MindMed in the ER whereby MindMed, among other errors, underre |
MindMed to Participate in the Jefferies London Healthcare ConferenceMind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022. |
MindMed Reports Third Quarter 2022 Financial Results and Business HighlightsMind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2022. |
Mind Medicine’s Bad Trip Won’t End Anytime SoonTrouble abounds as Mind Medicine proposes a huge sale of MNMD stock shares and an activist investor threatens the company's board. |
MNMD Price Returns
| 1-mo | -7.85% |
| 3-mo | -77.02% |
| 6-mo | -82.69% |
| 1-year | -90.91% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -86.96% |
| 2021 | -54.75% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...